| Bioactivity | IHCH-3064 is a dual-acting compounds targeting Adenosine A2A Receptor and HDAC. IHCH-3064 exhibits potent binding to A2AR (Ki=2.2 nM) and selective inhibition of HDAC1 (IC50=80.2 nM), with good antiproliferative activity against tumor cell lines in vitro. IHCH-3064 is a tumor immunotherapeutic agent[1]. |
| Name | IHCH-3064 |
| CAS | 2420562-65-6 |
| Formula | C25H21N9O2 |
| Molar Mass | 479.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wenzhong Yan, et al. Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A 2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents. J Med Chem. 2021 Nov 25;64(22):16573-16597. |
IHCH-3064
CAS: 2420562-65-6 F: C25H21N9O2 W: 479.49
IHCH-3064 is a dual-acting compounds targeting Adenosine A2A Receptor and HDAC. IHCH-3064 exhibits potent binding to A2
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.